BioNTech will seek EU approval to use vaccine in children age 12 to 15 April 29, 2021 The German laboratory BioNTech has told Euronews it plans to submit an application in the EU for authorization for the use of its COVID-19 vaccine with Pfizer in children aged 12 to 15. — Courtesy photo BRUSSELS — The German laboratory BioNTech has told Euronews it plans to submit an application in the EU for authorization for the use of its COVID-19 vaccine with Pfizer in children aged 12 to 15. The pharmaceutical company said it could have collected data for children younger than this age bracket by September. BioNTech/Pfizer said in March that its vaccine has proven to be 100 percent effective in youngsters aged 12 to 15.